Life Science Real Estate Vacancy Dips to 23.9% in Q3 2026; Newmark Puts It at 27%
U.S. life science real estate vacancy fell 20 basis points to 23.9% in the third quarter of 2026, the first decline in four years, Cushman & Wakefield reported on November 13, 2026.
Newmark, in a separate report covered by Bisnow the same day, put national lab vacancy at 27%. The two numbers measure different pools of buildings, so they should be read side by side, not blended.
Both firms point the same way: more tenants are looking, AI companies are taking lab space, and new construction is shrinking. Both also say rents and property values remain under pressure. This is a different release from the Savills data in our earlier post on life science vacancy in Boston, the Bay Area and San Diego.
By the Numbers
- 23.9%: national life science vacancy in the third quarter of 2026, down from 24.1% in the second quarter (Cushman & Wakefield report).
- 2.9 million square feet: third quarter leasing, up 11% from the second quarter, with net absorption of nearly 500,000 square feet (Cushman & Wakefield).
- 5.2 million square feet: lab space under construction, down 40% from a year earlier, with build-to-suit projects at 73% of the total (Cushman & Wakefield).
- $62.85: average asking rent per square foot, down 5.6% from a year earlier (Cushman & Wakefield).
- 27%: national lab vacancy in the third quarter, according to Newmark, as reported by Bisnow.
- 63%: rise in active tenant requirements in Boston, the Bay Area, Seattle and San Diego since the mid-2025 low, per Newmark via Bisnow.
What Cushman & Wakefield Found in the Third Quarter
Net absorption, the change in occupied space, turned positive at 483,520 square feet in the quarter, the Cushman & Wakefield report shows. Even so, net absorption for the year to date stayed negative, the firm said.
Leasing reached 2,894,132 square feet. Boston led with about 906,000 square feet, followed by the San Francisco Bay Area at about 829,000 and San Diego at about 346,000 (Cushman & Wakefield report).
"The market is starting to move in a healthier direction after an extended period of adjustment," said Sandy Romero, Head of Office and Alternative Insights at Cushman & Wakefield (Cushman & Wakefield). She added that the development pipeline "has come down significantly."
The firm said vacancy has "likely peaked" and expects it to trend lower over the next year, with some short-term swings (Cushman & Wakefield MarketBeat). It also expects rents to keep softening until demand strengthens further.
Life Science Vacancy 2026: Why 23.9% and 27% Differ
The 3.1-point gap between the two national readings does not mean one firm is wrong. Each firm builds its own inventory of lab buildings, picks its own markets and counts vacant space its own way.
Cushman & Wakefield's inventory covers about 238.9 million square feet across 13 markets. It includes lab and cGMP (current good manufacturing practice) space in office and industrial buildings, plus some owner-occupied properties (Cushman & Wakefield report).
Owner-occupied buildings sit in that inventory, but the firm does not count them as unoccupied space. That method can pull the vacancy rate lower. Sublet space that a tenant still occupies is also not counted as available, per the Cushman & Wakefield report.
Newmark tracks 13 top life science hubs using its own proprietary database, according to its third quarter 2025 report. That report noted its tracking method had been revised, which can shift historical figures.
Market by market, the readings also diverge. Newmark put Bay Area vacancy at 27.3%, down from 28.4% (Bisnow). Cushman & Wakefield put the Bay Area at 28.5% for the third quarter (Cushman & Wakefield report).
For investors, the practical rule is simple. Compare each firm's number with its own history, not with another firm's number. Averaging the two would mix inventories that were never built to match.
AI and Quantum Firms Add Demand for Lab Space
Newmark found 6.9 million square feet of leasing through the first nine months of 2026 across Boston, the Bay Area, Seattle and San Diego, according to Bisnow. Requirements from AI and quantum science companies are rising as landlords try to backfill space left by traditional lab users.
Newmark's chart shows total tenant demand in those four markets at 9.4 million square feet in the third quarter of 2026, up from 5.8 million at the second quarter 2025 low (Newmark via Bisnow).
Boston also saw AI growth: leasing requirements in the first three quarters rose 68% from 2025, and Anthropic and Blitzy signed leases in Kendall Square this year, Bisnow reported.
Newmark tied the Bay Area vacancy decline to strong performance by local AI and tech companies (Bisnow). That fits a wider pattern of AI firms filling existing buildings, covered in our post on AI office leasing and the Modal Labs lease.
Life Science Real Estate Rents and Values Remain Under Pressure
Rents fell in eight of the 13 largest life science markets, Newmark found, according to Bisnow. Cushman & Wakefield's national asking rent fell to $62.85 per square foot from $65.88 at the end of 2025 (Cushman & Wakefield report).
Not every market slid. Los Angeles-Orange County and Philadelphia posted annual rent growth, per Cushman & Wakefield. Philadelphia's asking rent rose to $49.44 in the third quarter, and its vacancy of 6.8% was among the lowest tracked (Cushman & Wakefield report).
Values are a separate concern. Life science property values have fallen 38% from their 2022 peak, Newmark said, citing the Green Street Commercial Property Price Index, as reported by Bisnow. That drop is steeper than the office market's pandemic-era decline, Bisnow noted.
Those markdowns show up in landlord results too. Our post on Alexandria Real Estate earnings and lab impairments covers how the largest lab landlord is writing down buildings it plans to sell.
Sales, Venture Capital and IPOs
Research and development property sales totaled $3.0 billion in the third quarter, up 50% from a year earlier, and average pricing rose 13% (Cushman & Wakefield). Buyers making opportunistic purchases of repriced assets drove much of that volume.
Newmark said investor interest has improved but "buyers remain selective," and expects occupiers to keep using depressed values for owner-user purchases (Bisnow).
On funding, Cushman & Wakefield counted $7.9 billion of venture capital in the third quarter, with year-to-date funding up 6% (Cushman & Wakefield). IPOs raised $7.3 billion through three quarters, nearly four times the same period of 2025. Newmark put biotech venture funding at $11.5 billion through the third quarter, per Bisnow, a figure built on a different data set.
Morabito Investment Group Analysis: Three Hubs Drive the Recovery
Boston, the Bay Area and San Diego accounted for about 72% of third quarter lab leasing nationwide, according to a Morabito Investment Group analysis of the Cushman & Wakefield report. Their combined 2.08 million square feet was divided by the 2.89 million national total.
Those three markets hold about 53% of the firm's tracked inventory, so their leasing is running well ahead of their share of space. That pattern suggests tenant demand is concentrating in the deepest, most established research clusters.
Supply math points the same way. By the same analysis, about 1.4 million of the 5.2 million square feet under construction is not build-to-suit, based on the 73% build-to-suit share reported by Cushman & Wakefield.
What It Means for Investors, Owners and Developers
A first quarterly vacancy decline is a signal, not a recovery. Vacancy near 24% to 27% still means roughly a quarter of tracked lab space is empty, depending on the firm.
Repriced buildings in core clusters are drawing buyers, and alternative users like AI firms are widening the tenant pool. With speculative construction this thin, well-located existing buildings face less new competition.
Owners and developers can find related coverage on our commercial real estate sector page.
Frequently Asked Questions
What is the life science real estate market report for Q3 2026?
Cushman & Wakefield's Q3 2026 U.S. Life Sciences MarketBeat, released November 13, 2026, put national vacancy at 23.9% (Cushman & Wakefield). Newmark's third quarter report put national lab vacancy at 27%, according to Bisnow.
What is life science vacancy in 2026?
It depends on the source. Cushman & Wakefield reported 23.9% in the third quarter of 2026, its first decline in four years (Cushman & Wakefield). Newmark reported 27% for the same quarter, as covered by Bisnow.
What is life science real estate?
It is space built for research labs and related uses. Cushman & Wakefield's inventory counts lab and cGMP manufacturing space in office and industrial buildings (Cushman & Wakefield report).
Key Takeaways
- Cushman & Wakefield reported national life science vacancy of 23.9% in the third quarter of 2026, its first quarterly decline in four years.
- Newmark measured national lab vacancy at 27%, and the gap reflects different inventories and methods, not a contradiction.
- Boston, the Bay Area and San Diego produced about 72% of third quarter leasing, according to a Morabito Investment Group analysis of Cushman & Wakefield data.
Bottom Line
Life science real estate may have found its floor in the third quarter of 2026, with leasing up and the pipeline down. Still, two major firms put vacancy between 23.9% and 27%, and rents fell in most of the largest markets while values sit well below their 2022 peak.
Image credit: Photo by Tony Webster, via Wikimedia Commons, licensed CC BY 2.0.
Sources
- Cushman & Wakefield, Cushman & Wakefield Reports Early Signs of Stabilization in U.S. Life Sciences Real Estate Market During Third Quarter, https://www.cushmanwakefield.com/en/united-states/news/2026/11/q3-2026-us-life-sciences-marketbeat
- Cushman & Wakefield, Life Sciences MarketBeat, https://www.cushmanwakefield.com/en/united-states/insights/us-marketbeats/life-sciences-marketbeat
- Cushman & Wakefield, MarketBeat U.S. National Life Sciences Q3 2026, https://content.cushmanwakefield.com/api/public/content/31aed53a6c7e48fbbd748f368b5a933a?v=fe1e6367
- Bisnow, AI Helps Drive New Demand For Lab Buildings, But Property Values Remain 'Depressed', https://www.bisnow.com/news/national/life-sciences/ai-helps-drive-new-demand-for-lab-buildings-but-property-values-remain-depressed-
- Newmark, 3Q25 U.S. Life Science Market Conditions & Trends, https://nmrk.imgix.net/uploads/images/3Q25-US-Life-Science-Market-Conditions-Trends-Short.pdf
Disclaimer: This article is for general information and education only. It is not investment, financial, legal, tax or accounting advice, and it is not an offer or solicitation to buy or sell any security or property. Morabito Investment Group does not guarantee that the information is complete, accurate or current. Figures, forecasts and opinions from third parties belong to their sources. All investments carry risk, including loss of principal, and past results do not guarantee future results. Do your own research and consult a licensed professional before making any investment, financing or other decision. You use this information at your own risk.
This article is for general information only. It is not legal, tax, financial, or investment advice, and it is not an offer to sell or a solicitation of an offer to buy any security. Talk to your own advisors before acting on anything in it. Views are current as of the publish date and may change without notice.








